WHO Issues Alert Over Acute Lack of Obesity Jabs
Less than 10% of people that would benefit from GLP-1 drugs like Wegovy are able to get them, states the World Health Organization as it issues its first recommendations on the medications.
With over a billion individuals worldwide currently living with obesity, it is urging broader and more equitable availability to these injectable treatments.
According to forecasts, more than two billion are projected to be living with obesity by 2030 unless action is taken.
"The new guidance acknowledges that obesity is a long-term condition that can be treated with thorough and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are key obstacles to widespread access to the treatments that can help people shift considerable body mass, says the agency.
Skinny Jab Scarcity
Despite the current most optimistic outlook, the manufacturing of these medications could only cover approximately 100 million people – fewer than 10% of the global need, per the WHO.
The guideline urges nations and manufacturers to expand access, via strategies including patent sharing.
The intellectual property rights on semaglutide – the main ingredient of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
How Weight-Loss Drugs Work
These medications replicate a biological compound to delay gastric emptying, suppress the appetite and enhance feelings of fullness so people reduce food intake.
Patients commonly start to lose weight after several weeks of beginning the once-weekly jabs.
Research points to patients may regain a significant portion a year later of stopping the treatment, because their typical appetite resume.
To be carrying excess weight increases your chance for experiencing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity impacts people in all nations and was linked to millions of fatalities worldwide in 2024, according to the WHO.
